UNSPSC 51401707: Captodiame hydrochloride

This classification denotes an anxiolytic with the molecular formula C21H29NS2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9I7N9PR9J2, chemically known as 2((p-(butylthio)-alpha-phenylbenzyl)thio)-n,n-dimethylethylamine hydrochloride but more generally known as captodiame hydrochloride, which bears US NIH Compound Identifier 13484. European Medicines Agency schedules Captodiame hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01035MIG.

Most nations, for tariff and trade purposes, schedule captodiame hydrochloride under HS 29309085. As of Q4 2014, CAPTODIAME HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Captodiame hydrochloride bears US NLM identifiers UMLS ID C2698983 and NCI Concept Code C76504. SMILES: CCCCSC1CCC(CC1)C(C2CCCCC2)SCCN(C)C.CL.

UNSPSC 51401707 Captodiame hydrochloride is a Commodity code that does not match the work actually being solicited under it in recent state and local procurement. The three opportunities on record—Seminole County's naloxone and drug deactivation systems procurement, the Texas HHS Commission's therapeutic pharmacy initiative RFI, and the Minnesota Multistate Cooperative Purchasing Alliance's generic multi-source pharmaceuticals RFP—involve naloxone, direct-to-manufacturer prescription programs, and broad-based OTC and generic drug supply, respectively. None of these solicitations reference captodiame hydrochloride or pharmaceutical compounds matching that therapeutic class. The code shows minimal recent activity aligned with its nominal scope, and the opportunities present under it appear to reflect either mislabeling in state procurement systems or a substantial divergence between the code's intended use and current buying patterns.

The geographic activity visible in these three records spans Florida, Texas, and Minnesota, with the MMCAP cooperative extending to Oregon and other participating jurisdictions. Issuing bodies include a county health department (Seminole County), a state health agency (Texas HHS Commission), and a multistate cooperative purchasing vehicle (MMCAP administered by Minnesota). The representative opportunities—Seminole County's IFB60459723LAS due July 26, 2023 for naloxone units and deactivation systems; Texas HHS's RFI HHS0017013 posted April 3, 2026 for direct-to-manufacturer prescription capabilities; and MMCAP's S1070000015802 RFP with a March 26, 2026 response deadline for generic pharmaceuticals and OTC products through authorized wholesalers—indicate that state and local procurement under this code designation is primarily driven by health benefit programs, emergency medical supply chains, and cooperative purchasing alliances rather than the specific active pharmaceutical ingredient this code nominally describes.